Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study

• DOI: 10.1007/s12325-021-01982-6
• Publication Date: 2021-11-22T07:02:31Z
• Authors: Kari Kelton; Tim Klein; Dan Murphy; Mark Belger; Erik Hille; Patrick L. McCollam; Theodore Spiro; Russel Burge
• Keywords: Reimbursement

Baricitinib–remdesivir (BARI-REM) combination is superior to remdesivir (REM) in reducing recovery time and accelerating clinical improvement among hospitalized patients with coronavirus disease 2019 (COVID-19), specifically those receiving high-flow oxygen/noninvasive ventilation. Here we assessed the cost-effectiveness of BARI-REM versus REM COVID-19 USA. A three-state model was developed addressing costs patient utility associated hospitalization, immediate post hospital care, subsequent lifetime medical care. Analysis performed from perspective a payer hospital. Both perspectives evaluated two subgroups: all who required oxygen. The primary measures benefit were quality-adjusted life years (QALYs) accrued during after cost per gained, death avoided, use mechanical ventilation avoided. In base-case horizon, treatment resulted an incremental total $7962, gain 0.446 0.3565 QALYs over REM. ratios using estimated as $22,334 QALY $17,858 year. sensitivity analyses showed that falls within reduced willingness-to-pay threshold $50,000/QALY applied under health emergencies. patients, expenditures by $1778 reimbursement payments $1526, resulting $252 reduction net patient; it also 0.0018 increased survival hospitalizations 2.7%. Our study cost-effective compared for COVID-19. results this most sensitive average annual recovered patients.